Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma
Kai Huang(Nanchang University), Chunsheng Kang(Tianjin Medical University General Hospital), Qixue Wang(Tianjin Medical University General Hospital), Junhu Zhou(Tianjin Medical University General Hospital), Tao Jiang(Beijing Tian Tan Hospital), Chaoyong Liu(Beijing University of Chemical Technology), Xing Liu(Capital Medical University), Yunfei Wang(First Affiliated Hospital of Xinxiang Medical University), Yansheng Li(Tianjin Medical University General Hospital), Chao Yang(Tianjin Medical University General Hospital), Zhiyan Sun(Tongji University), Feng Dong(Tianjin Medical University), Xudong Wu(Tianjin Medical University General Hospital), Chuan Fang(Affiliated Hospital of Hebei University), Yanli Tan(Peking University)
Cited by 106
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas
|Genome Research|2014|425
Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status
|Laboratory Investigation|2010|362
Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy
|Molecular Cell|2017|282
A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas
|NeuroImage Clinical|2018|262